News
FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer
The FDA has said it cannot approve MSD and Daiichi Sankyo’s HER3-targeted antibody-drug conjugate (ADC) patritumab deruxtecan because of problems at a third-party manufacturer.
